TAKEDA PHARMACEUTICALS AMERICA INC — Lobbying Disclosure | Poliscope

TAKEDA PHARMACEUTICALS AMERICA INC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$60.6M

Filings

401

Firms Hired

Active Period

2000–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$3,470,000	16	6
2025	$5,540,000	25	6
2024	$3,250,000	25	7
2023	$4,600,000	28	7
2022	$4,870,000	25	7
2021	$7,090,000	35	9
2020	$5,450,000	26	6
2019	$3,460,000	25	6
2018	$2,970,000	23	6
2017	$3,430,000	19	5
2016	$1,348,000	17	4
2015	$1,512,000	17	4
2014	$1,831,000	19	4
2013	$1,609,469	16	4
2012	$1,742,475	16	4
2011	$2,825,000	15	3
2010	$1,681,094	12	3
2009	$3,044,295	16	3
2008	$830,000	16	3
2007	—	3	1
2001	$40,000	2	1
2000	$0	5	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TAKEDA PHARMACEUTICALS AMERICA INC	$60,593,333	99
WILLIAMS AND JENSEN, PLLC	—	60
CROSSROADS STRATEGIES, LLC	—	57
OGR	—	38
PORTERFIELD, FETTIG & SEARS, LLC	—	32
TIBER CREEK GROUP	—	23
TARPLIN, DOWNS & YOUNG, LLC	—	23
HOLLAND & KNIGHT LLP	—	21
TODD STRATEGY GROUP	—	16
ALPINE GROUP PARTNERS, LLC.	—	14
BAKER & MCKENZIE LLP	—	15
CUNNINGHAM-BOWERS, KELLY	—	3

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	377
SENATE	358
Centers For Medicare and Medicaid Services (CMS)	65
Health & Human Services, Dept of (HHS)	38
Food & Drug Administration (FDA)	28
Treasury, Dept of	23
Health Resources & Services Administration (HRSA)	21
Agency for Healthcare Research & Quality (AHRQ)	17
Executive Office of the President (EOP)	17
Defense, Dept of (DOD)	15
Medicare Payment Advisory Commission (MedPAC)	14
White House Office	10
Office of Management & Budget (OMB)	7
Substance Abuse & Mental Health Services Administration (SAMHSA)	6
Centers For Disease Control & Prevention (CDC)	3
Office of the Vice President of the United States	3
Veterans Affairs, Dept of (VA)	3
Environmental Protection Agency (EPA)	2
Internal Revenue Service (IRS)	1
Natl Institutes of Health (NIH)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	315
Medicare/Medicaid	Medicare/Medicaid	293
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	193
Budget/Appropriations	Budget/Appropriations	151
Trade (domestic/foreign)	Trade (domestic/foreign)	96
Copyright/Patent/Trademark	Copyright/Patent/Trademark	56
Manufacturing	Manufacturing	29
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	25
Defense	Defense	15
Government Issues	Government Issues	12
Clean Air and Water (quality)	Clean Air and Water (quality)	10
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	10
Pharmacy	Pharmacy	6
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	5
Food Industry (safety, labeling, etc.)	Food Industry (safety, labeling, etc.)	3
Veterans	Veterans	3
Environment/Superfund	Environment/Superfund	3
Civil Rights/Civil Liberties	Civil Rights/Civil Liberties	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R.1

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 4299

H.R. 4581119th Congress

340B PATIENTS Act of 2025

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 4581

H.R. 5256119th Congress

340B ACCESS Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 5256

Show 21 more cited filings

H.R. 6609119th Congress

Pharmacists Fight Back in Medicare and Medicaid Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 6609

H.R. 7837119th Congress

Most Favored Patient Act of 2026

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 7837

H.R. 8269119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 8269

H.R. 9599119th Congress

SECURE 340B Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: H.R. 9599

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 1040

S. 1095119th Congress

Stop STALLING Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S.1095

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 1096

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 1954

S. 2372119th Congress

340B PATIENTS Act of 2025

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 2372

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 2658

S. 832119th Congress

EPIC Act of 2025

2026 · third_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order

Client expense: $1,450,000 · Firm income: —

Matched citations: S. 832

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4299

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · third_quarter · Firm: TODD STRATEGY GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R.4299

S. 891119th Congress

Bipartisan Health Care Act

2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Client expense: — · Firm income: $50,000

Matched citations: S.891

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · second_quarter · Firm: TODD STRATEGY GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R.4299

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Client expense: $610,000 · Firm income: —

Matched citations: H.R.1

H.R. 4229119th Congress

To amend the Impoundment Control Act of 1974 to require prior approval from Congress before the Comptroller General may pursue a civil action under such Act, and for other purposes.

2026 · second_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Client expense: $610,000 · Firm income: —

Matched citations: HR 4229

H.R. 946119th Congress

ORPHAN Cures Act

2026 · second_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Client expense: $610,000 · Firm income: —

Matched citations: H.R. 946

S. 832119th Congress

EPIC Act of 2025

2026 · second_quarter · Firm: TAKEDA PHARMACEUTICALS AMERICA INC

Open original LDA filing ↗

Cited source text and reported amounts

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Client expense: $610,000 · Firm income: —

Matched citations: S. 832

H.R. 4299119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4299

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1

Source: Senate LDA